Turning Away from RA
Syk ’Em: Rigel Taking On ITP; Amgen, GSK Game to Change?
By Randy Osborne
Thursday, September 5, 2013
Not surprisingly, Rigel Pharmaceuticals Inc. has decided not to pursue the oral spleen tyrosine kinase (Syk) inhibitor fostamatinib in rheumatoid arthritis (RA) after Astrazeneca plc, unhappy with trial data, returned the rights to the compound last month.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.